A clinical study of 57 children with fetal anticonvulsant syndromes

Journal of Medical Genetics

Volumn 37, Issue 7, 2000, Pages 489-497

  Moore, S J ^a   Turnpenny, P ^b   Quinn, A ^b   Glover, S ^b   Lloyd, D J ^c   Montgomery, T ^d   Dean, J C S ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^c ABERDEEN MATERNITY HOSPITAL   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Birth defects; Fetal anticonvulsant syndrome; Fetal valproate syndrome; Teratogen

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ARTICLE; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; CHILD; FEMALE; FETUS; HUMAN; INFANT; JOINT LAXITY; LEARNING DISORDER; MAJOR CLINICAL STUDY; MALE; MUCOID OTITIS MEDIA; PRENATAL DRUG EXPOSURE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SPEECH DISORDER;

EID: 0033934755     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.37.7.489     Document Type: Article

References (43)

1. Eller DP, Patterson CA, Webb GW. Maternal and fetal implications of anticonvulsive therapy during pregnancy. Obstet Gynecol Clin North Am 1997;24:523-35.
2. Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 1992;42(suppl 5):149-60.
3. ACOG educational bulletin. Seizure disorders in pregnancy. Int J Gynaecol Obstet 1997;56:279-86.
4. Kelly TE. Teratogenicity of anticonvulsant drugs. Am J Med Genet 1984;19:413-34.
5. Meadow R. Anticonvulsants in pregnancy. Arch Dis Child 1991;66:62-5.
6. Clayton-Smith J, Donnai D. Fetal valproate syndrome. J Med Genet 1995;32:724-7.
7. Jick SS, Terris BZ. Anticonvulsants and congenital malformations. Pharmacotherapy 1997;17:561-4.
8. Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994;271:767-70.
9. DiLiberti JH, Farndon PA, Dennis NR, Curry CJR. The fetal valproate syndrome. Am J Med Genet 1984;19:473-81.
10. Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975:87:285-90.
11. Jones KLJ, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989;320: 1661-6.
12. Nulman I, Scolnik D, Chitayat D, Farkas LD, Koren G. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. Am J Med Genet 1997;68:18-24.
13. Vestermark V, Vestermark S. Teratogenic effect of carbamazepine. Arch Dis Child 1991;66:641-2.
14. Ardinger HH, Atkin JF, Blackston D, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988;29:171-85.
15. Winter RM, Donnai D, Burn J, Tucker SM. Fetal valproate syndrome: is there a recognisable phenotype? J Med Genet 1987;24:692-5.
16. Thisted E, Ebbesen F. Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. Arch Dis Child 1993;69:288-91.
17. Omtzigt JGC, Los FJ, Hagenaars AM, Stewart PA, Sachs ES, Lindhout D. Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenat Diagn 1992;12:893-7.
18. Omtzigt JGC, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992;42(suppl 5):119-25.
19. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324: 674-7.
20. Beighton P, Solomon L, Soskolne CL. Articular mobility in an African population. Ann Rheum Dis 1973;32:413-18
21. Dean JCS, Moore SJ, Osborne A, Howe J, Turnpenny PD. Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene. Clin Genet 1999;56:216-20.
22. Emery AEH. Methodology in medical genetics. Edinburgh: Churchill Livingstone, 1986:51.
23. Lindhout D, Meinardi H, Meijer JWA, Nau H. Antiepileptic drugs and teratogenesis in two consecutive cohorts. Neurology 1992;42(suppl 5):94-110.
24. Battino D, Bimelli S, Caccamo ML, et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurol Scand 1992;85:204-7.
25. Leonard G, Ptito A, Seni MH, et al. Cognitive performance in school-age offspring of epileptic mothers exposed to anticonvulsant therapy (AED) during pregnancy. Am J Hum Genet 1995;57(suppl);A136.
26. Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996;75:517-20.
27. D'Souza SW, Robertson IG, Donnai D, Mawer G. Fetal phenytoin exposure, hypoplastic nails and jitteriness. Arch Dis Child 1990;65:320-4.
28. Lindhout D, Hoppener RJEA, Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia 1984;25:77-83.
29. Waterston T, Platt MW, Helms P. Paediatrics, understanding child health. Oxford: Oxford University Press, 1997:227.
30. Hoyt CS, Billson FA. Maternal anticonvulsants and optic nerve hypoplasia. Br J Ophthalmol 1978;62:3-6.
31. Sutcliffe AG, Jones RB, Woodruff G. Eye malformations associated with treatment with carbamazepine during pregnancy. Ophthal Genet 1998;19:59-62.
32. Astley SJ, Clarren SK. A case definition and photographic screening tool for the facial phenotype of fetal alcohol syndrome. J Pediatr 1996;129:33-41.
33. Autti-Ramo I, Gaily E, Granstrom ML. Dysmorphic features in offspring of alcoholic mothers. Arch Dis Child 1992;67:712-16.
34. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to epileptic drugs. Epilepsy Res 1999;33: 145-58.
35. Koch S, Jager-Roman E, Losche G, Nau H, Rating D, Helge H. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatr Scand 1996;85:739-46.
36. Hanson JW, Myrianthopoulos NC, Harvey MAS, Smith DW. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J Pediatr 1976;89:662-8.
37. Shapiro S, Slone D, Hartz SC, et al. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1976;i:272-5.
38. Nelson KB, Ellenberg JH. Maternal seizure disorder, outcome of pregnancy, and neurologic abnormalities in the children. Neurology 1982;32:1247-54.
39. Gaily E, Kantola-Sorsa E, Granstrom ML. Intelligence of children of epileptic mothers. J Pediatr 1988;113:677-84.
40. Gaily E, Kantola-Sorsa E, Granstrom ML. Specific cognitive dysfunction in children with epileptic mothers. Dev Med Child Neurol 1990;32:403-14.
41. Bennett GD, Lau F, Calvin JA, Finnell RH. Phenytoin-induced teratogenesis: a molecular basis for the observed developmental delay during neurulation. Epilepsia 1997;38: 415-23.
42. Christianson AL, Chesler N, Kromberg JGR. Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. Dev Med Child Neurol 1994;36:361-9.
43. Williams PG, Hersh JH. A male with fetal valproate syndrome and autism. Dev Med Child Neurol 1997;39:632-4.